Clinical trials: Multiple Sclerosis Spasticity
Multiple Sclerosis
Exopulse Mollii Suit, Spasticity & Tissue Oxygenation
Spasticity is a frequent and debilitating symptom in patients with multiple sclerosis (MS). Sustained contractile activity, such as that observed in spastic muscles, could reduce the capillary density and induce important changes…
- Trial name
- ENNOX (NCT05362006)
- Testing
- Exopulse Mollii Suit
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Institut De La Colonne Vertebrale Et Des Neurosciences
Multiple Sclerosis
Evaluation of a Spasticity Management Program for People With Multiple Sclerosis
This study will examine the impacts of two different methods of managing MS-related spasticity of the lower limbs. Both interventions will be presented via video teleconference in group classes consisting of exercises to reduce…
- Trial name
- STC (NCT03166930)
- Testing
- Spasticity Take Control, Stretching for People with MS: An Illustrated Manual
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- VA Office of Research and Development
Herpesviridae Infection, HTLV-I Infection
Assessment of Patients With Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a disease of the nervous system. The exact cause of MS is unknown, but it is believed to be an autoimmune condition.
- Conditions
- Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis
- Trial name
- NCT00001156
- Where
- United States
- Volunteers
- 1,388 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Muscle Spasticity, Multiple Sclerosis
Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients
The purpose of this study is to determine if Xeomin® will prove effective for significantly improving lower extremity spasticity and will be well tolerated by the majority of MS patients.
- Trial name
- NCT01968902
- Testing
- incabotulinumtoxinA
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Multiple Sclerosis Center of Northeastern New York
Muscle Spasticity
MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study
Study Objectives: To determine the efficacy and safety of a standardised extract of Cannabis sativa given orally 2 times daily as compared to placebo for the relief of muscle stiffness and pain in multiple sclerosis for a period…
- Trial name
- MUSEC (NCT00552604)
- Testing
- standardized cannabis extract
- Where
- United Kingdom
- Volunteers
- 279 people
- Sponsor
- Institut fur Klinische Forschung, Germany
ALS, Autism Spectrum Disorder
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
This is an observational study of medical marijuana manufactured and dispensed by Ilera and given as standard treatment for a variety of approved serious medical conditions as defined by individual state law.
- Conditions
- ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle
- Trial name
- Ilera (NCT03886753)
- Testing
- Registry, PK microsampling of blood
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Philadelphia
Spasticity in Participants With Multiple Sclerosis
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols as adjunctive therapy compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Modified Ashworth Scale…
- Trial name
- RELEASE MSS1 (NCT04657666)
- Testing
- Nabiximols
- Where
- 16 sites in Czechia, Poland
- Volunteers
- 68 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to…
- Trial name
- NCT00681538
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 572 people
- Sponsor
- Jazz Pharmaceuticals
Centreal Neurological Condition, Acquired Brain Injury (Including Stroke)
Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities
Spasticity is an umbrella term for impairments of muscle tone and control in people with damage to the brain and spinal cord. It is highly prevalent and results in pain, stiffness, and contribute to difficulties in activities of…
- Conditions
- Centreal Neurological Condition, Acquired Brain Injury (Including Stroke), Multiple Sclerosis, Spinal Cord Injury
- Trial name
- ICE (NCT07303582)
- Testing
- Cryoneurolysis, Botulinum toxin
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Oxford University Hospitals NHS Trust
Spasticity, Multiple Sclerosis
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity.
- Trial name
- NCT01743651
- Testing
- arbaclofen, baclofen
- Where
- 48 sites in United States, Russia and 1 more
- Volunteers
- 353 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis
Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS
In an individual with MS the central nervous system (CNS) is over-protective and causes the threshold for stretch reflex and muscle tightness to be set lower than normal.
- Trial name
- NCT04942938
- Testing
- Neubie
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- CommonSpirit Health
Stroke, Multiple Sclerosis
Interest of a Musical Intervention on Stress Induced During Botulinum Toxin Injections in Spasticity (MUSIBOT)
Botulinum toxin (BT) injections are a painful treatment frequently used to treat spasticity following central neurological damage (stroke, multiple sclerosis, spinal cord injury, head trauma).
- Conditions
- Stroke, Multiple Sclerosis, Spinal Cord Injury, Head Trauma Injury
- Trial name
- MUSIBOT (NCT06920524)
- Testing
- Intervention group IM-IM
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Clermont-Ferrand
Multiple Sclerosis, Muscle Spasticity
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride…
- Conditions
- Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
- Trial name
- NCT00047580
- Testing
- tizanidine hydrochloride capsule
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Elan Pharmaceuticals
Multiple Sclerosis, Spasticity
Developing and Testing a Comprehensive MS Spasticity Management Program
This is a study to determine the impact of education and specific lower extremity stretches for MS-related spasticity. The study will evaluate the acceptance and efficacy of education and stretching using a randomized controlled…
- Trial name
- NCT02170779
- Testing
- Spasticity: Take Control, Usual care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the Central Nervous System (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain…
- Trial name
- NCT00053417
- Testing
- 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
- Where
- 25 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Acorda Therapeutics
Chronic Brain Injury, Cerebral Stroke
Qualitative Study Patient & Physician Experiences Botox COVID-19
During the COVID-19 pandemic and subsequent series of Lockdowns, clinic out-patient spasticity services were replaced with video based tele-consultation appointments, in order to reduce the potential risk of virus transmission…
- Conditions
- Chronic Brain Injury, Cerebral Stroke, MS (Multiple Sclerosis)
- Trial name
- QualBotoxCov (NCT05435404)
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- East Kent Hospitals University NHS Foundation Trust
Multiple Sclerosis
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
- Trial name
- NCT01359566
- Testing
- Arbaclofen placarbil 15 mg BID, Arbaclofen placarbil 30 mg BID, Arbaclofen placarbil 45 mg BID
- Where
- 28 sites in United States
- Volunteers
- 228 people
- Sponsor
- XenoPort, Inc.
Multiple Sclerosis, Spasticity, Muscle
" Treating MS Patients With Lower Extremity Spasticity Using Dysport"
The purpose of this study is to determine whether Dysport® (abobotulinumtoxinA) injections for lower extremity spasticity showed a significant reduction of lower extremity spasticity after being injected with Dysport®…
- Trial name
- NCT03585569
- Testing
- Abobotulinumtoxin A
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neurology Center of New England P.C.
Multiple Sclerosis
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
The purpose of this study is to determine the effects, both good and bad, of IPX056 on subjects and their spasticity. This study will also determine the relationship between the amount of IPX056 in blood and the effects on…
- Trial name
- NCT00488839
- Testing
- IPX056 20 mg, IPX056 40 mg, Encapsulated Baclofen 20 mg
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 173 people
- Sponsor
- Impax Laboratories, LLC
Multiple Sclerosis Spasticity
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- Trial name
- MSS (NCT06782490)
- Testing
- BMS-986368
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- Celgene